Goal-directed medical therapy has reshaped nephrology, but in patients with frailty, advanced age, or complex multimorbidity, the calculus is less clear. This debate confronts the tension between guideline-driven polypharmacy and patient-centred deprescribing, asking whether universal GDMT is an evidence-based imperative or an oversimplification that ignores the realities of patients living with multimorbidity. Expect sharp arguments, clinical nuance, and no easy answers.
| Time | Session |
|---|---|
|
16:15
16:35
|
For aggressive GDMT
|
|
16:35
16:55
|
Against aggressive GDMT
|
|
16:55
17:15
|
Q&A
|